Technical Field
The present disclosure relates to surgical instruments, systems, and methods. More particularly, the present disclosure relates to surgical instruments, systems, and methods for sealing tissue structures such as bowel (intestine) tissue or other similar tissue structures.
Description of Related Art
Approximately 2.5 million bowel fusion or anastomosis procedures are performed worldwide each year. Fusion and anastomosis of the bowel has traditionally been accomplished using sutures and/or staples.
Energy-based surgical instruments and systems, as an alternative or in addition to suturing and/or stapling, utilize both mechanical clamping action and energy, e.g., radiofrequency (RF) energy, to affect hemostasis by heating tissue to coagulate and/or cauterize tissue. Certain surgical procedures require more than simply coagulating/cauterizing tissue and rely on the unique combination of clamping pressure, precise energy control, and/or gap distance between sealing surfaces to “seal” tissue. Depending on the particular tissue structure to be sealed, the optimal parameters, e.g., clamping pressure, precise energy control, and/or gap distance, may vary.
A method of sealing bowel tissue (or other similar tissue structures) provided in accordance with the present disclosure includes grasping bowel tissue between first and second electrically-conductive surfaces, applying a clamping pressure to the grasped bowel tissue in a range of about 1 kg/cm2 to about 2.5 kg/cm2, supplying energy to the first and/or second electrically-conductive surface such that the energy is conducted between the surfaces and through the grasped bowel tissue to seal the grasped bowel tissue, and monitoring one or more parameters during the supplying of energy to the surface(s). The one or more parameters may be bowel tissue temperature, bowel tissue impedance, an optical property of bowel tissue, and/or sealing time.
With regard to bowel tissue temperature, the method may include controlling the supply of energy to the surface(s) to maintain the bowel tissue temperature between a lower temperature limit and an upper temperature limit. More specifically, the lower temperature limit may correspond to the minimum bowel tissue temperature for sealing bowel tissue, while the upper temperature limit may correspond to the maximum bowel tissue temperature prior to occurrence of bowel tissue denaturation, bowel tissue damage, and/or breakdown of bowel tissue layer architecture.
With regard to bowel tissue impedance, the method may include controlling the supply of energy to the surface(s) to maintain a target impedance ramp, e.g., about 0.010 Ω/ms, and/or supplying energy to the surface(s) until bowel tissue impedance reaches a target end impedance, e.g., about 200Ω.
With regard to one or more optical properties of bowel tissue, the method may include supplying energy to the surface(s) until the optical property of bowel tissue indicates bowel tissue denaturation, bowel tissue damage, and/or breakdown of bowel tissue layer architecture.
With regard to sealing time, the method may include supplying energy to the surface(s) for a sealing time of between about 18 and 22 seconds.
Another method of sealing bowel tissue provided in accordance with the present disclosure includes grasping bowel tissue with an applied clamping pressure in a range of about 1 kg/cm2 to about 2.5 kg/cm2, supplying energy to the grasped bowel tissue, and controlling the supply of energy to the grasped bowel tissue such that the grasped bowel tissue is sufficiently sealed with minimal bowel tissue denaturation, bowel tissue damage, and breakdown of bowel tissue layer architecture. Controlling the supply of energy includes monitoring one or more parameters and providing control based on the one or more parameters.
In one aspect of the present disclosure, the parameter is bowel tissue temperature and controlling the supply of energy includes maintaining the bowel tissue temperature between a lower temperature limit, corresponding to the minimum bowel tissue temperature for sealing bowel tissue, and an upper temperature limit, corresponding to the maximum bowel tissue temperature prior to occurrence of at least one of bowel tissue denaturation, bowel tissue damage, and breakdown of bowel tissue layer architecture.
In another aspect of the present disclosure, the parameter is bowel tissue impedance and controlling the supply of energy includes maintaining a target impedance ramp, e.g., about 0.010 Ω/ms, and/or supplying energy until bowel tissue impedance reaches a target end impedance, e.g., about 200Ω.
In still yet another aspect of the present disclosure, the parameter is an optical property of bowel tissue and controlling the supply of energy includes supplying energy until the optical property of bowel tissue indicates bowel tissue denaturation, bowel tissue damage, and/or breakdown of bowel tissue layer architecture.
Also provided in accordance with the present disclosure are instruments, end effector assemblies, generators, and systems suitable for use in accordance with the above-detailed methods.
Various aspects and features of the present disclosure are described herein with reference to the drawings wherein like reference numerals identify similar or identical elements:
The present disclosure relates generally to surgical devices and methods for applying energy, e.g., RF energy, to bowel (intestine) tissue or other similar tissue structures to treat, e.g., seal, tissue. Referring to
Continuing with reference to
With continued reference to
End effector assembly 100 is shown attached at the distal end 16 of shaft 12 and includes opposing jaw members 110 and 120. Each jaw member 110, 120 includes an electrically-conductive tissue-contacting surface 112, 122, respectively, that cooperate to grasp tissue therebetween and seal grasped tissue upon application of energy from generator 40. More specifically, tissue-contacting surfaces 112, 122 are electrically coupled to generator 40, e.g., via wires 56a, 56b, and are configured to conduct RF energy provided by generator 40 between tissue-contacting surfaces 112, 122 and through tissue grasped therebetween to treat, e.g., seal, tissue. Other suitable forms of energy, e.g., thermal, microwave, light, ultrasonic, etc., are also contemplated. Either or both jaw members 110, 120 may further include one or more non-conductive stop members 124 (
An activation switch 30 is disposed on housing 20 and is coupled between generator 40 and tissue-contacting surfaces 112, 122 via wire 56c. Activation switch 30 is selectively activatable to provide energy from generator 40 to tissue-contacting surface 112 of jaw member 110 (and/or tissue-contacting surface 122 of jaw member 120) of end effector assembly 100. More specifically, when activation switch 30 is depressed, a resistance drop across circuitry 32 is recognized by generator 40 to initiate electrosurgical energy to supply a first electrical potential to jaw member 110 and a second electrical potential to jaw member 120.
End effector assembly 100 is designed as a bilateral assembly, i.e., wherein both jaw member 110 and jaw member 120 are movable about a pivot 19 relative to one another and to shaft 12. However, end effector assembly 100 may alternatively be configured as a unilateral assembly, i.e., wherein one of the jaw members, e.g., jaw member 120, is fixed relative to shaft 12 and the other jaw member, e.g., jaw member 110, is movable about pivot 19 relative to shaft 12 and the fixed jaw member 120.
In some embodiments, a knife assembly (not shown) is disposed within shaft 12 and a knife channel 115 is defined within one or both jaw members 110, 120 to permit reciprocation of a knife blade (not shown) therethrough, e.g., via actuation of trigger assembly 25, to cut tissue grasped between jaw members 110, 120. Alternatively or additionally, end effector assembly 100 may be configured for energy-based tissue cutting.
Referring to
Turning now to
With tissue grasped between jaw members 110, 120 under the specific clamping pressure (or clamping pressure within a specific clamping pressure range), energy may be supplied to either or both tissue-contacting surfaces 112, 122 of jaw members 110, 120, respectively, to seal tissue. The particular sealing parameters provided in accordance with the present disclosure that have been found to be particularly applicable for use in sealing bowel tissue or other similar tissue structures are detailed below.
Turning now to
Either or both jaw members 310, 320 of end effector assembly 300 may further include a sensor 316, 326 positioned adjacent the respective tissue-contacting surface 312, 322 and configured to sense one or more parameters, e.g., tissue impedance, tissue temperature, current and/or voltage applied to tissue, etc., and/or one or more tissue properties, e.g., optical tissue properties, physical tissue properties, etc. Sensors 316, 326 are coupled to the source of energy, e.g., generator 400 (
Controller 424 includes a microprocessor 425 operably connected to a memory 426 which may be volatile type memory (e.g., RAM) and/or non-volatile type memory (e.g., flash media, disk media, etc.). Microprocessor 425 is operably connected to HVPS 427 and/or RF output stage 428 allowing microprocessor 425 to control the output of generator 400, e.g., in accordance with feedback received from sensor circuitry 422. Sensor circuitry 422 is operably coupled to wires 314, 324, which provide and return energy to/from tissue-contacting surfaces 312, 322 (
With respect to controlling the output of generator 400 based upon tissue impedance, as mentioned above, tissue impedance can be monitored via sensor circuitry 22. More specifically, tissue impedance can be monitored relative to a target end impedance, e.g., the peak relative increase in impedance from a baseline value, while the monitored tissue impedances values can also be utilized to determine an impedance ramp, e.g., the rate of increase/decrease of tissue impedance as a function of time, as compared to a target impedance ramp. Depending on the particular target values set (and stored in memory 426, for example), microprocessor 425 may accordingly provide for automatic adjustment or control of the power and/or energy output of generator 400. A clock (not shown) may also be provided for controlling sealing time (the amount of time energy is supplied to tissue), in conjunction with the above-described impedance control. Impedance and/or sealing time control may be utilized to inhibit tissue denaturation, damage, tissue layer architecture breakdown, etc. A specific implementation of impedance feedback-based control particularly suited for sealing bowel tissue or other similar tissue structures is detailed below.
With respect to controlling the output of generator 400 based upon optical tissue properties, sensors 316, 318 (
Any of the above-detailed end effector assemblies, instruments, and systems, may also be configured to work with robotic surgical systems and what is commonly referred to as “telesurgery.” Such robotic systems employ various robotic elements to assist the surgeon in the operating theater and allow remote operation (or partial remote operation) of the end effector assembly and surgical instrumentation. Various robotic arms, gears, cams, pulleys, electric and mechanical motors, etc. may be employed for this purpose and may be designed with a robotic surgical system to assist the surgeon during the course of an operation or treatment. Such robotic systems may include remotely steerable systems, automatically flexible surgical systems, remotely flexible surgical systems, remotely articulating surgical systems, wireless surgical systems, modular or selectively configurable remotely operated surgical systems, etc.
The robotic surgical systems may be employed with one or more consoles that are next to the operating theater or located in a remote location. In this instance, one team of surgeons or nurses may prep the patient for surgery and configure the robotic surgical system with surgical instrumentation and/or an end effector assembly, e.g., any of those disclosed hereinabove, while another surgeon (or group of surgeons) remotely controls the end effector assembly and/or other instrumentation via the robotic surgical system. As can be appreciated, a highly skilled surgeon may perform multiple operations in multiple locations without leaving his/her remote console which can be both economically advantageous and a benefit to the patient or a series of patients.
The robotic arms of the surgical system are typically coupled to a pair of master handles by a controller. The handles can be moved by the surgeon to produce corresponding movement, manipulation, and/or actuation of the end effector assembly, e.g., to position the end effector assembly, grasp tissue, supply energy to tissue, deploy a knife for cutting tissue, release tissue, etc. The master handles may include various sensors to provide feedback to the surgeon relating to various tissue parameters or conditions, e.g., tissue resistance due to manipulation, cutting or otherwise treating, pressure by the instrument onto the tissue, tissue temperature, tissue impedance, etc. As can be appreciated, such sensors provide the surgeon with enhanced tactile feedback simulating actual operating conditions. These sensors and feedback systems may be incorporated into and/or work in conjunction with the sensors and feedback systems of the instruments, end effector assemblies, and/or generators detailed hereinabove. The master handles may further include a variety of different actuators for delicate tissue manipulation or treatment to further enhancing the surgeon's ability to mimic actual operating conditions.
Sealing bowel tissue and other similar tissue structures has been found to require different sealing parameters, e.g., clamping pressure, gap distance, and/or energy control, as compared to sealing blood vessels, vascular tissue, and the like, due to differences in tissue composition and structure as well as differences in the physiological utilizations of these tissues. More specifically, bowel tissue is thicker and more muscular tissue as compared to blood vessels and vascular tissue. Bowel tissue is also more sensitive and is required to maintain function after sealing to fulfill its role in the digestive and excretory processes. As a result of the particular composition and functions of bowel tissue, a balance must be struck between the interest of ensuring formation of an adequate seal and the competing interest of minimizing denaturation, damage, tissue layer architecture breakdown, etc. of the tissue (which is typically not a concern with regard to sealing blood vessels and vascular tissues). It is contemplated that the above-described mechanisms, instruments, systems, end effector assemblies, generators, etc., alone or in combination with one another, be utilized to seal bowel tissue in accordance with these considerations, as described in detail below.
Taking into account the above-identified considerations, it has been found that a clamping pressure in the range of about 1 kg/cm2 to about 2.5 kg/cm2 applies sufficient pressure to bowel tissue to enable formation of an adequate bowel seal through merging of tissue layers, while also inhibiting/minimizing denaturation, damage, tissue layer architecture breakdown, etc. That is, bowel tissue seals have been found to be inadequate when formed using clamping pressures below about 1 kg/cm2, while the level of tissue denaturation, damage, overall tissue layer architecture breakdown, etc. has been found to negatively effect the viability and/or performance of the sealed bowel tissue when formed using clamping pressures above 2.5 kg/cm2. During sealing, the clamping pressure may be regulated and maintained within this clamping pressure range via use of any of the mechanisms detailed above or described in U.S. Pat. Nos. 5,776,130; 7,766,910; 7,771,426; and 8,226,650; and/or U.S. Patent Application Pub. Nos. 2009/0292283; 2012/0172873; and 2012/0184988, previously incorporated by reference herein, or via any other suitable methods or mechanisms.
With respect to gap distance, any suitable gap distance (constant or varied) between the tissue-contacting surfaces of the jaw members may be used during the sealing cycle so as to regulate and/or maintain the clamping pressure within the above-identified clamping pressure range throughout a portion of or the entire sealing cycle. The gap distance may likewise be maintained via use of any of the mechanisms detailed above or those described in U.S. Pat. Nos. 5,776,130; 7,766,910; 7,771,426; and 8,226,650; and/or U.S. Patent Application Pub. Nos. 2009/0292283; 2012/0172873; and 2012/0184988, previously incorporated by reference herein, or via any other suitable methods or mechanisms.
With respect to energy control, it has been found that an effective bowel seal, using a clamping pressure within the range of about 1 kg/cm2 to about 2.5 kg/cm2, can be established via temperature feedback-based energy control, optical tissue property feedback-based energy control, and/or impedance feedback-based energy control, e.g., using a feedback based system such as that detailed above with respect to end effector assembly 300 (
Temperature control may be utilized to adjust the energy output such that tissue is sufficiently heated to enable formation of an effective tissue seal, but is maintained at a temperature below the temperature at which denaturation, damage, tissue layer architecture breakdown, etc. occurs.
Impedance control can be implemented to adjust the energy output using a target end impedance of about 200Ω and a target impedance ramp of about 0.010 Ω/ms, so as to ensure that the tissue is adequately sealed without damaging or negatively altering the tissue. Further, such impedance-control provides for a sealing cycle time typically in the range of about 18 to 22 seconds and, thus, tissue sealing time can also be utilized as feedback parameter.
Optical tissue property control may be utilized, as mentioned above, to adjust the energy output to inhibit denaturation, damage, breakdown of tissue layer architecture, etc. during the tissue sealing cycle by monitoring one or more properties or indications of such, e.g., changes in the collagen matrix of tissue, denaturation of tissue, changes in tissue layer architecture, etc.
While several embodiments of the disclosure have been shown in the drawings and/or discussed herein, it is not intended that the disclosure be limited thereto, as it is intended that the disclosure be as broad in scope as the art will allow and that the specification be read likewise. Therefore, the above description should not be construed as limiting, but merely as exemplifications of particular embodiments. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto.
This application is a continuation application of U.S. patent application Ser. No. 14/017,572, filed on Sep. 4, 2013, now U.S. Pat. No. 9,433,461, which claims the benefit of, and priority to, U.S. Provisional Patent Application No. 61/698,270, filed on Sep. 7, 2012, the entire contents of each of which are hereby incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
D249549 | Pike | Sep 1978 | S |
D263020 | Rau, III | Feb 1982 | S |
D295893 | Sharkany et al. | May 1988 | S |
D295894 | Sharkany et al. | May 1988 | S |
D298353 | Manno | Nov 1988 | S |
D299413 | DeCarolis | Jan 1989 | S |
D343453 | Noda | Jan 1994 | S |
D348930 | Olson | Jul 1994 | S |
D349341 | Lichtman et al. | Aug 1994 | S |
D354564 | Medema | Jan 1995 | S |
D358887 | Feinberg | May 1995 | S |
5443463 | Stern et al. | Aug 1995 | A |
D384413 | Zlock et al. | Sep 1997 | S |
H1745 | Paraschac | Aug 1998 | H |
D402028 | Grimm et al. | Dec 1998 | S |
D408018 | McNaughton | Apr 1999 | S |
D416089 | Barton et al. | Nov 1999 | S |
D424694 | Tetzlaff et al. | May 2000 | S |
D425201 | Tetzlaff et al. | May 2000 | S |
6123701 | Nezhat | Sep 2000 | A |
H1904 | Yates et al. | Oct 2000 | H |
D449886 | Tetzlaff et al. | Oct 2001 | S |
D453923 | Olson | Feb 2002 | S |
D454951 | Bon | Mar 2002 | S |
D457958 | Dycus et al. | May 2002 | S |
D457959 | Tetzlaff et al. | May 2002 | S |
H2037 | Yates et al. | Jul 2002 | H |
D465281 | Lang | Nov 2002 | S |
D466209 | Bon | Nov 2002 | S |
6676660 | Wampler et al. | Jan 2004 | B2 |
6702810 | McClurken et al. | Mar 2004 | B2 |
D493888 | Reschke | Aug 2004 | S |
6775575 | Bommannan et al. | Aug 2004 | B2 |
D496997 | Dycus et al. | Oct 2004 | S |
D499181 | Dycus et al. | Nov 2004 | S |
D502994 | Blake, III | Mar 2005 | S |
D509297 | Wells | Sep 2005 | S |
6953461 | McClurken et al. | Oct 2005 | B2 |
D525361 | Hushka | Jul 2006 | S |
D531311 | Guerra et al. | Oct 2006 | S |
7115139 | McClurken et al. | Oct 2006 | B2 |
D533274 | Visconti et al. | Dec 2006 | S |
D533942 | Kerr et al. | Dec 2006 | S |
D535027 | James et al. | Jan 2007 | S |
D538932 | Malik | Mar 2007 | S |
D541418 | Schechter et al. | Apr 2007 | S |
D541611 | Aglassinger | May 2007 | S |
D541938 | Kerr et al. | May 2007 | S |
D545432 | Watanabe | Jun 2007 | S |
D547154 | Lee | Jul 2007 | S |
D564662 | Moses et al. | Mar 2008 | S |
D567943 | Moses et al. | Apr 2008 | S |
D575395 | Hushka | Aug 2008 | S |
D575401 | Hixson et al. | Aug 2008 | S |
D582038 | Swoyer et al. | Dec 2008 | S |
D617900 | Kingsley et al. | Jun 2010 | S |
D617901 | Unger et al. | Jun 2010 | S |
D617902 | Twomey et al. | Jun 2010 | S |
D617903 | Unger et al. | Jun 2010 | S |
D618798 | Olson et al. | Jun 2010 | S |
D621503 | Otten et al. | Aug 2010 | S |
D627462 | Kingsley | Nov 2010 | S |
D628289 | Romero | Nov 2010 | S |
D628290 | Romero | Nov 2010 | S |
D630324 | Reschke | Jan 2011 | S |
7909820 | Lipson et al. | Mar 2011 | B2 |
7976544 | McClurken et al. | Jul 2011 | B2 |
D649249 | Guerra | Nov 2011 | S |
D649643 | Allen, IV et al. | Nov 2011 | S |
8128624 | Couture et al. | Mar 2012 | B2 |
D661394 | Romero et al. | Jun 2012 | S |
8192444 | Dycus | Jun 2012 | B2 |
8382754 | Odom et al. | Feb 2013 | B2 |
8679140 | Butcher | Mar 2014 | B2 |
RE44834 | Dumbauld et al. | Apr 2014 | E |
8777945 | Floume et al. | Jul 2014 | B2 |
8968311 | Allen, IV et al. | Mar 2015 | B2 |
9433461 | Arya | Sep 2016 | B2 |
20040162596 | Altshuler | Aug 2004 | A1 |
20050033278 | McClurken et al. | Feb 2005 | A1 |
20060052779 | Hammill | Mar 2006 | A1 |
20060217709 | Couture et al. | Sep 2006 | A1 |
20080172048 | Martin et al. | Jul 2008 | A1 |
20090018535 | Schechter et al. | Jan 2009 | A1 |
20090204114 | Odom | Aug 2009 | A1 |
20100217258 | Floume | Aug 2010 | A1 |
20130245623 | Twomey | Sep 2013 | A1 |
20130247343 | Horner et al. | Sep 2013 | A1 |
20130253489 | Nau, Jr. et al. | Sep 2013 | A1 |
20130255063 | Hart et al. | Oct 2013 | A1 |
20130267948 | Kerr et al. | Oct 2013 | A1 |
20130267949 | Kerr | Oct 2013 | A1 |
20130274736 | Garrison | Oct 2013 | A1 |
20130282010 | McKenna et al. | Oct 2013 | A1 |
20130289561 | Waaler et al. | Oct 2013 | A1 |
20130296854 | Mueller | Nov 2013 | A1 |
20130296922 | Allen, IV et al. | Nov 2013 | A1 |
20130296923 | Twomey et al. | Nov 2013 | A1 |
20130304058 | Kendrick | Nov 2013 | A1 |
20130304059 | Allen, IV et al. | Nov 2013 | A1 |
20130304066 | Kerr et al. | Nov 2013 | A1 |
20130310832 | Kerr et al. | Nov 2013 | A1 |
20130325057 | Larson et al. | Dec 2013 | A1 |
20130331837 | Larson | Dec 2013 | A1 |
20130338666 | Bucciaglia et al. | Dec 2013 | A1 |
20130338693 | Kerr et al. | Dec 2013 | A1 |
20130345701 | Allen, IV et al. | Dec 2013 | A1 |
20130345706 | Garrison | Dec 2013 | A1 |
20130345735 | Mueller | Dec 2013 | A1 |
20140005663 | Heard et al. | Jan 2014 | A1 |
20140005666 | Moua et al. | Jan 2014 | A1 |
20140005667 | Stulen | Jan 2014 | A1 |
20140025052 | Nau, Jr. et al. | Jan 2014 | A1 |
20140025053 | Nau, Jr. et al. | Jan 2014 | A1 |
20140025059 | Kerr | Jan 2014 | A1 |
20140025060 | Kerr | Jan 2014 | A1 |
20140025066 | Kerr | Jan 2014 | A1 |
20140025067 | Kerr et al. | Jan 2014 | A1 |
20140025070 | Kerr et al. | Jan 2014 | A1 |
20140025073 | Twomey et al. | Jan 2014 | A1 |
20140031821 | Garrison | Jan 2014 | A1 |
20140031860 | Stoddard et al. | Jan 2014 | A1 |
20140046323 | Payne et al. | Feb 2014 | A1 |
20140066910 | Nau, Jr. | Mar 2014 | A1 |
20140066911 | Nau, Jr. | Mar 2014 | A1 |
20140074091 | Arya et al. | Mar 2014 | A1 |
20140100564 | Garrison | Apr 2014 | A1 |
20140100568 | Garrison | Apr 2014 | A1 |
Number | Date | Country |
---|---|---|
201299462 | Sep 2009 | CN |
2415263 | Oct 1975 | DE |
02514501 | Oct 1976 | DE |
2627679 | Jan 1977 | DE |
03423356 | Jun 1986 | DE |
03612646 | Apr 1987 | DE |
8712328 | Feb 1988 | DE |
0403882 | Feb 1995 | DE |
04403252 | Aug 1995 | DE |
19515914 | Jul 1996 | DE |
19506363 | Aug 1996 | DE |
29616210 | Nov 1996 | DE |
19608716 | Apr 1997 | DE |
19751106 | May 1998 | DE |
19751108 | May 1999 | DE |
19946527 | Jul 2001 | DE |
20121161 | Apr 2002 | DE |
10045375 | Oct 2002 | DE |
202007009165 | Aug 2007 | DE |
202007009317 | Aug 2007 | DE |
202007009318 | Aug 2007 | DE |
10031773 | Nov 2007 | DE |
202007016233 | Jan 2008 | DE |
19738457 | Jan 2009 | DE |
102004026179 | Jan 2009 | DE |
102008018406 | Jul 2009 | DE |
1159926 | Mar 2003 | EP |
61-501068 | Sep 1984 | JP |
11-47150 | Jun 1989 | JP |
6-502328 | Mar 1992 | JP |
5-5106 | Jan 1993 | JP |
05-40112 | Feb 1993 | JP |
0006030945 | Feb 1994 | JP |
6-121797 | May 1994 | JP |
6-285078 | Oct 1994 | JP |
6-511401 | Dec 1994 | JP |
06343644 | Dec 1994 | JP |
07265328 | Oct 1995 | JP |
08056955 | Mar 1996 | JP |
08252263 | Oct 1996 | JP |
8-289895 | Nov 1996 | JP |
8-317934 | Dec 1996 | JP |
8-317936 | Dec 1996 | JP |
09000538 | Jan 1997 | JP |
09010223 | Jan 1997 | JP |
9-122138 | May 1997 | JP |
H10-24051 | Jan 1998 | JP |
10-155798 | Jun 1998 | JP |
11-070124 | Mar 1999 | JP |
11-169381 | Jun 1999 | JP |
11-192238 | Jul 1999 | JP |
11244298 | Sep 1999 | JP |
2000-102545 | Apr 2000 | JP |
2000-135222 | May 2000 | JP |
2000342599 | Dec 2000 | JP |
2000350732 | Dec 2000 | JP |
2001008944 | Jan 2001 | JP |
2001029356 | Feb 2001 | JP |
2001-03400 | Apr 2001 | JP |
2001128990 | May 2001 | JP |
2001-190564 | Jul 2001 | JP |
2002-136525 | May 2002 | JP |
2002-528166 | Sep 2002 | JP |
2003-116871 | Apr 2003 | JP |
2003-175052 | Jun 2003 | JP |
2003245285 | Sep 2003 | JP |
2004-517668 | Jun 2004 | JP |
2004-528869 | Sep 2004 | JP |
2005-152663 | Jun 2005 | JP |
2005-253789 | Sep 2005 | JP |
2006-015078 | Jan 2006 | JP |
2006-501939 | Jan 2006 | JP |
2006-095316 | Apr 2006 | JP |
0011125195 | Jun 2011 | JP |
2011125195 | Jun 2011 | JP |
401367 | Nov 1974 | SU |
0036986 | Jun 2000 | WO |
00593292 | Oct 2000 | WO |
0115614 | Mar 2001 | WO |
0154604 | Aug 2001 | WO |
0245589 | Jun 2002 | WO |
2006021269 | Mar 2006 | WO |
05110264 | Apr 2006 | WO |
08040483 | Apr 2008 | WO |
Entry |
---|
Michael Choti, “Abdominoperineal Resection with the LigaSure Vessel Sealing System and LigaSure Atlas 20 cm Open Instrument” Innovations That Work, .quadrature.Jun. 2003. |
Chung et al., “Clinical Experience of Sutureless Closed Hemorrhoidectomy with LigaSure” Diseases of the Colon & Rectum vol. 46, No. 1 Jan. 2003. |
Tinkcler L.F., “Combined Diathermy and Suction Forceps” , Feb. 6, 1967 (Feb. 6, 1965), British Medical Journal Feb. 6, 1976, vol. 1, nr. 5431 p. 361, ISSN: 0007-1447. |
Carbonell et al., “Comparison of theGyrus PlasmaKinetic Sealer and the Valleylab LigaSure Device in the Hemostasis of Small, Medium, and Large-Sized Arteries” Carolinas Laparoscopic and Advanced Surgery Program, Carolinas Medical Center,Charlotte,NC; Date: Aug. 2003. |
Peterson et al. “Comparison of Healing Process Following Ligation with Sutures and Bipolar Vessel Sealing” Surgical Technology International (2001). |
“Electrosurgery: A Historical Overview” Innovations in Electrosurgery; Sales/Product Literature; Dec. 31, 2000. |
Johnson et al. “Evaluation of a Bipolar Electrothermal Vessel Sealing Device in Hemorrhoidectomy” Sales/Product Literature; Jan. 2004. |
E. David Crawford “Evaluation of a New Vessel Sealing Device in Urologic Cancer Surgery” Sales/Product Literature 2000. |
Johnson et al. “Evaluation of the LigaSure Vessel Sealing System in Hemorrhoidectormy” American College of Surgeons (ACS) Clinicla Congress Poster (2000). |
Muller et al., “Extended Left Hemicoletomy Using the LigaSure Vessel Sealing System” Innovations That Work,. quadrature.Sep. 1999. |
Kennedy et al. “High-burst-strength, feedback-controlled bipolar vessel sealing” Surgical Endoscopy (1998) 12:876-878. |
Burdette et al. “In Vivo Probe Measurement Technique for Determining Dielectric Properties at VHF Through Microwave Frequencies”, IEEE Transactions on Microwave Theory and Techniques, vol. MTT-28, No. 4, Apr. 1980 pp. 414-427. |
Carus et al., “Initial Experience With the LigaSure Vessel Sealing System in Abdominal Surgery” Innovations That Work,.quadrature.Jun. 2002. |
Heniford et al. “Initial Results with an Electrothermal Bipolar Vessel Sealer” Surgical Endoscopy (2000) 15:799-801. |
Herman et al., “Laparoscopic Intestinal Resection With the LigaSure Vessel Sealing System: A Case Report”; Innovations That Work, Feb. 2002. |
Koyle et al., “Laparoscopic Palomo Varicocele Ligation in Children and Adolescents” Pediatric Endosurgery & Innovative Techniques, vol. 6, No. 1, 2002. |
W. Scott Helton, “LigaSure Vessel Sealing System: Revolutionary Hemostasis Product for General Surgery”; Sales/Product Literature 1999. |
LigaSure Vessel Sealing System, the Seal of Confidence in General, Gynecologic, Urologic, and Laparaoscopic Surgery; Sales/Product Literature; Apr. 2002. |
Joseph Ortenberg “LigaSure System Used in Laparoscopic 1st and 2nd Stage Orchiopexy” Innovations That Work, Nov. 2002. |
Sigel et al. “The Mechanism of Blood Vessel Closure by High Frequency Electrocoagulation” Surgery Gynecology & Obstetrics, Oct. 1965 pp. 823-831. |
Sampayan et al, “Multilayer Ultra-High Gradient Insulator Technology” Discharges and Electrical Insulation in Vacuum, 1998. Netherlands Aug. 17-21, 1998; vol. 2, pp. 740-743. |
Paul G. Horgan, “A Novel Technique for Parenchymal Division During Hepatectomy” The American Journal of Surgery, vol. 181, No. 3, Apr. 2001 pp. 236-237. |
Benaron et al., “Optical Time-Of-Flight and Absorbance Imaging of Biologic Media”, Science, American Association for the Advancement of Science, Washington, DC, vol. 259, Mar. 5, 1993, pp. 1463-1466. |
Palazzo et al. “Randomized clinical trial of Ligasure versus open haemorrhoidectomy” British Journal of Surgery 2002, 89, 154-157. |
Levy et al. “Randomized Trial of Suture Versus Electrosurgical Bipolar Vessel Sealing in Vaginal Hysterectomy” Obstetrics & Gynecology, vol. 102, No. 1, Jul. 2003. |
“Reducing Needlestick Injuries in the Operating Room” Sales/Product Literature 2001. |
Bergdahl et al. “Studies on Coagulation and the Development of an Automatic Computerized Bipolar Coagulator” J. Neurosurg, vol. 75, Jul. 1991, pp. 148-151. |
Strasberg et al. “A Phase I Study of the LigaSure Vessel Sealing System in Hepatic Surgery” Section of HPB Surger, Washington University School of Medicine, St. Louis MO, Presented at AHPBA, Feb. 2001. |
Seyfan et al. “Sutureless Closed Hemorrhoidectomy: A New Technique” Annals of Surgery vol. 234 No. 1, Jul. 2001 pp. 21-24. |
Levy et al., “Update on Hysterectomy—New Technologies and Techniques” OBG Management, Feb. 2003. |
Dulemba et al. “Use of a Bipolar Electrothermal Vessel Sealer in Laparoscopically Assisted Vaginal Hysterectomy” Sales/Product Literature; Jan. 2004. |
Strasberg et al., “Use of a Bipolar Vessel-Sealing Device for Parenchymal Transection During Liver Surgery” Journal of Gastrointestinal Surgery, vol. 6, No. 4, Jul./Aug. 2002 pp. 569-574. |
Sengupta et al., “Use of a Computer-Controlled Bipolar Diathermy System in Radical Prostatectomies and Other Open Urological Surgery” ANZ Journal of Surgery (2001) 71.9 pp. 538-540. |
Rothenberg et al. “Use of the LigaSure Vessel Sealing System in Minimally Invasive Surgery in Children” Int'l Pediatric Endosurgery Group (IPEG) 2000. |
Crawford et al. “Use of the LigaSure Vessel Sealing System in Urologic Cancer Surgery” Grand Rounds in Urology 1999 vol. 1 Issue 4 pp. 10-17. |
Craig Johnson. “Use of the LigaSure Vessel Sealing System in Bloodless Hemorrhoidectomy” That Work, Mar. 2000. |
Levy et al. “Use of a New Energy-based Vessel Ligation Device During Vaginal Hysterectomy” Int'l Federation of Gynecology and Obstetrics (FIGO) World Congress 1999. |
Barbara Levy, “Use of a New Vessel Ligation Device During Vaginal Hysterectomy” FIGO 2000, Washington, D.C. |
E. David Crawford “Use of a Novel Vessel Sealing Technology in Management of the Dorsal Veinous Complex” Sales/Product Literature 2000. |
Crouch et al. “A Velocity-Dependent Model for Needle Insertion in Soft Tissue” MICCAI 2005; LNCS 3750 pp. 624-632, dated: 2005. |
McLellan et al. “Vessel Sealing for Hemostasis During Pelvic Surgery” Int'l Federation of Gynecology and Obstetrics FIGO World Congress 2000, Washington, D.C. |
McLellan et al. “Vessel Sealing for Hemostasis During Gynecologic Surgery” Sales/Product Literature 1999. |
U.S. Appl. No. 08/926,869, filed Sep. 10, 1997; inventor: Chandler. |
U.S. Appl. No. 09/177,950, filed Oct. 23, 1998; inventor: Frazie. |
U.S. Appl. No. 09/387,883, filed Sep. 1, 1999; inventor: Schmaltz. |
U.S. Appl. No. 09/591,328, filed Jun. 9, 2000; inventor: Ryan. |
U.S. Appl. No. 12/336,970, filed Dec. 17, 2008; inventor: Sremcich. |
U.S. Appl. No. 13/731,674, filed Dec. 31, 2012; inventor: Siebrecht. |
Number | Date | Country | |
---|---|---|---|
20160310206 A1 | Oct 2016 | US |
Number | Date | Country | |
---|---|---|---|
61698270 | Sep 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14017572 | Sep 2013 | US |
Child | 15200176 | US |